Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Therma Bright Announces Shares for Debt Issuance to Include Portfolio Company AI4LYF & IR Agreement

In This Article:

Toronto, Ontario--(Newsfile Corp. - September 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, announces that AI4LYF has agreed to participate in a shares for debt transaction which progresses the Company's contractual obligation to AI4LYF while preserving cash.

Therma Bright is the global exclusive license holder of the innovative AI-powered Digital Cough Technology (DCT) which was created by AI4LYF and funded by Therma Bright As shared in August 2024, the DCT is currently being considered as a partner technology for a new, innovative, and disruptive chronic cough drug U.S.-based clinical trial. Furthermore, the Company, along with AI4LYF, is pursuing U.S. Food and Drug Administration (FDA) 513(g) request to obtain information regarding the classification and regulatory requirements for this AI-powered technology to be used as a remote therapeutic monitoring (RTM) solution. In a 2023 Precedence Research report, the "global respiratory monitoring devices market size accounted for USD $1.50 billion in 2022, and it is expected to hit around USD 2.99 billion by 2032".

The Company has negotiated debt settlements with arm's length and non-arm's length creditors. Pursuant to the debt settlements it has arranged, and subject to acceptance by the TSXV, the Company proposes to settle aggregate debt of $404,500 in consideration for which it will issue an aggregate of 5,056,250 common shares at a deemed price of $0.08 per share with AI4LYF participating for CAD $280,000 making up the bulk of the shares for debt issuance.

Directors and officers are participating in the debt settlement transactions and will receive an aggregate of 593,750 shares in consideration for settlement of an aggregate $47,500 debt. Participation by directors and officers will constitute a "related party transaction" as defined under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101"). Such participation is expected to be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of the securities that may be acquired by the insiders, nor the consideration for the securities that will be paid by such insiders, is expected to exceed 25% of the Company's market capitalization.

All securities issued under the debt settlements will be subject to a hold period expiring four months and one day from their date of issuance.